View ValuationCOSMOS Pharmaceutical 将来の成長Future 基準チェック /26COSMOS Pharmaceutical利益と収益がそれぞれ年間5.9%と7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に11.2% 5.9%なると予測されています。主要情報5.9%収益成長率5.89%EPS成長率Consumer Retailing 収益成長8.9%収益成長率7.0%将来の株主資本利益率11.20%アナリストカバレッジGood最終更新日05 Jun 2026今後の成長に関する最新情報分析記事 • Apr 15COSMOS Pharmaceutical Corporation (TSE:3349) Just Released Its Third-Quarter Earnings: Here's What Analysts ThinkLast week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its quarterly result to the...分析記事 • Jan 15COSMOS Pharmaceutical Corporation (TSE:3349) Half-Year Results Just Came Out: Here's What Analysts Are Forecasting For This YearThere's been a notable change in appetite for COSMOS Pharmaceutical Corporation ( TSE:3349 ) shares in the week since...分析記事 • Oct 16COSMOS Pharmaceutical Corporation Just Missed EPS By 8.0%: Here's What Analysts Think Will Happen NextCOSMOS Pharmaceutical Corporation ( TSE:3349 ) shareholders are probably feeling a little disappointed, since its...分析記事 • Jul 16Here's What Analysts Are Forecasting For COSMOS Pharmaceutical Corporation (TSE:3349) After Its Annual ResultsLast week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its annual result to the...分析記事 • Apr 16COSMOS Pharmaceutical Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextInvestors in COSMOS Pharmaceutical Corporation ( TSE:3349 ) had a good week, as its shares rose 8.8% to close at...分析記事 • Jan 17COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearShareholders of COSMOS Pharmaceutical Corporation ( TSE:3349 ) will be pleased this week, given that the stock price is...すべての更新を表示Recent updatesUpcoming Dividend • May 21Upcoming dividend of JP¥37.50 per shareEligible shareholders must have bought the stock before 28 May 2026. Payment date: 04 August 2026. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.8%). Lower than average of industry peers (2.0%).お知らせ • May 09COSMOS Pharmaceutical Corporation to Report Fiscal Year 2026 Results on Jul 13, 2026COSMOS Pharmaceutical Corporation announced that they will report fiscal year 2026 results on Jul 13, 2026分析記事 • Apr 15COSMOS Pharmaceutical Corporation (TSE:3349) Just Released Its Third-Quarter Earnings: Here's What Analysts ThinkLast week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its quarterly result to the...Reported Earnings • Apr 14Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: JP¥102 (up from JP¥99.87 in 3Q 2025). Revenue: JP¥273.2b (up 11% from 3Q 2025). Net income: JP¥8.10b (up 2.3% from 3Q 2025). Profit margin: 3.0% (down from 3.2% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 1.5%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Apr 03COSMOS Pharmaceutical Corporation to Report Q3, 2026 Results on Apr 13, 2026COSMOS Pharmaceutical Corporation announced that they will report Q3, 2026 results on Apr 13, 2026分析記事 • Feb 16COSMOS Pharmaceutical (TSE:3349) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Declared Dividend • Feb 13First half dividend of JP¥37.50 announcedShareholders will receive a dividend of JP¥37.50. Ex-date: 28th May 2026 Payment date: 4th August 2026 Dividend yield will be 1.0%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (19% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 17% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 19% over the next 3 years, which should provide support to the dividend and adequate earnings cover.分析記事 • Jan 15COSMOS Pharmaceutical Corporation (TSE:3349) Half-Year Results Just Came Out: Here's What Analysts Are Forecasting For This YearThere's been a notable change in appetite for COSMOS Pharmaceutical Corporation ( TSE:3349 ) shares in the week since...Reported Earnings • Jan 14Second quarter 2026 earnings: EPS misses analyst expectationsSecond quarter 2026 results: EPS: JP¥81.72 (up from JP¥79.30 in 2Q 2025). Revenue: JP¥264.8b (up 8.5% from 2Q 2025). Net income: JP¥6.48b (up 3.1% from 2Q 2025). Profit margin: 2.4% (down from 2.6% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.7%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 14Cosmos Pharmaceutical Corporation Announces Dividend for the Second Quarter-End of the Fiscal Year Ending May 31, 2026, Payable on February 12, 2026COSMOS Pharmaceutical Corporation announced dividend of JPY 37.50 per share for the second quarter-end of the fiscal year ending May 31, 2026 against JPY 32.50 per share paid a year ago. Scheduled date of commencing dividend payments is February 12, 2026.分析記事 • Nov 28Returns On Capital Signal Tricky Times Ahead For COSMOS Pharmaceutical (TSE:3349)There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Upcoming Dividend • Nov 20Upcoming dividend of JP¥37.50 per shareEligible shareholders must have bought the stock before 27 November 2025. Payment date: 12 February 2026. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.5%).分析記事 • Nov 13COSMOS Pharmaceutical (TSE:3349) Will Pay A Dividend Of ¥37.50COSMOS Pharmaceutical Corporation's ( TSE:3349 ) investors are due to receive a payment of ¥37.50 per share on 12th of...分析記事 • Nov 12Does COSMOS Pharmaceutical (TSE:3349) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Nov 05COSMOS Pharmaceutical Corporation to Report Q2, 2026 Results on Jan 13, 2026COSMOS Pharmaceutical Corporation announced that they will report Q2, 2026 results on Jan 13, 2026分析記事 • Oct 27COSMOS Pharmaceutical's (TSE:3349) Dividend Will Be ¥37.50The board of COSMOS Pharmaceutical Corporation ( TSE:3349 ) has announced that it will pay a dividend on the 12th of...分析記事 • Oct 16COSMOS Pharmaceutical Corporation Just Missed EPS By 8.0%: Here's What Analysts Think Will Happen NextCOSMOS Pharmaceutical Corporation ( TSE:3349 ) shareholders are probably feeling a little disappointed, since its...Reported Earnings • Oct 15First quarter 2026 earnings: EPS misses analyst expectationsFirst quarter 2026 results: EPS: JP¥103 (up from JP¥103 in 1Q 2025). Revenue: JP¥272.4b (up 4.0% from 1Q 2025). Net income: JP¥8.17b (flat on 1Q 2025). Profit margin: 3.0% (down from 3.1% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.0%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.分析記事 • Sep 17Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E RatioWith a price-to-earnings (or "P/E") ratio of 22.8x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...Declared Dividend • Sep 08Final dividend of JP¥37.50 announcedShareholders will receive a dividend of JP¥37.50. Ex-date: 27th November 2025 Payment date: 12th February 2026 Dividend yield will be 0.8%, which is lower than the industry average of 1.6%.Reported Earnings • Sep 02Full year 2025 earnings: Revenues and EPS in line with analyst expectationsFull year 2025 results: EPS: JP¥391 (up from JP¥309 in FY 2024). Revenue: JP¥1.01t (up 4.8% from FY 2024). Net income: JP¥31.0b (up 27% from FY 2024). Profit margin: 3.1% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 7% per year.分析記事 • Aug 15Here's Why We Think COSMOS Pharmaceutical (TSE:3349) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...お知らせ • Jul 30COSMOS Pharmaceutical Corporation to Report Q1, 2026 Results on Oct 14, 2025COSMOS Pharmaceutical Corporation announced that they will report Q1, 2026 results on Oct 14, 2025分析記事 • Jul 16Here's What Analysts Are Forecasting For COSMOS Pharmaceutical Corporation (TSE:3349) After Its Annual ResultsLast week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its annual result to the...Reported Earnings • Jul 14Full year 2025 earnings: Revenues and EPS in line with analyst expectationsFull year 2025 results: EPS: JP¥391 (up from JP¥309 in FY 2024). Revenue: JP¥1.01t (up 4.8% from FY 2024). Net income: JP¥31.0b (up 27% from FY 2024). Profit margin: 3.1% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 8% per year.お知らせ • Jul 13+ 3 more updatesCOSMOS Pharmaceutical Corporation Announces Year-End Dividend for the Fiscal Year Ended May 31, 2025, Payable on August 4, 2025COSMOS Pharmaceutical Corporation resolved to distribute dividends of surplus with a record date of May 31, 2025. The details of which are as below. Record date: May 31, 2025,Dividend per share JPY 37.50. Total amount of dividends: JPY 2,972 million . Effective date: August 4, 2025 Source of dividends Retained earnings as compared to the dividend of JPY 60.00 (JPY 30.00) per share paid an year ago. The Company conducted a 2-for-1 stock split effective September 1, 2024. Dividends per share for the fiscal year ended May 31, 2024 are based on the number of shares before such stock split. For your reference, the figure shown in parentheses represents the amount per share reflecting the aforementioned stock split.お知らせ • Jul 11COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 21, 2025COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 21, 2025.分析記事 • Jul 04Return Trends At COSMOS Pharmaceutical (TSE:3349) Aren't AppealingTo find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...分析記事 • Jun 02Is COSMOS Pharmaceutical (TSE:3349) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Upcoming Dividend • May 22Upcoming dividend of JP¥32.50 per shareEligible shareholders must have bought the stock before 29 May 2025. Payment date: 01 August 2025. Payout ratio is a comfortable 17% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Japanese dividend payers (4.0%). Lower than average of industry peers (1.7%).分析記事 • May 17Investor Optimism Abounds COSMOS Pharmaceutical Corporation (TSE:3349) But Growth Is LackingWith a price-to-earnings (or "P/E") ratio of 24.7x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...お知らせ • May 01COSMOS Pharmaceutical Corporation to Report Fiscal Year 2025 Results on Jul 11, 2025COSMOS Pharmaceutical Corporation announced that they will report fiscal year 2025 results on Jul 11, 2025分析記事 • Apr 16COSMOS Pharmaceutical Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextInvestors in COSMOS Pharmaceutical Corporation ( TSE:3349 ) had a good week, as its shares rose 8.8% to close at...Reported Earnings • Apr 15Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: EPS: JP¥99.87 (up from JP¥72.80 in 3Q 2024). Revenue: JP¥246.3b (up 3.1% from 3Q 2024). Net income: JP¥7.92b (up 37% from 3Q 2024). Profit margin: 3.2% (up from 2.4% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 31%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 12% per year.分析記事 • Mar 27Should You Be Adding COSMOS Pharmaceutical (TSE:3349) To Your Watchlist Today?It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • Mar 11COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The BusinessFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Declared Dividend • Feb 13First half dividend of JP¥32.50 announcedShareholders will receive a dividend of JP¥32.50. Ex-date: 29th May 2025 Payment date: 1st August 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.6%. Payout Ratios Payout ratio: 18%. Cash payout ratio: 146%.お知らせ • Feb 03COSMOS Pharmaceutical Corporation to Report Q3, 2025 Results on Apr 11, 2025COSMOS Pharmaceutical Corporation announced that they will report Q3, 2025 results on Apr 11, 2025分析記事 • Jan 31COSMOS Pharmaceutical Corporation's (TSE:3349) Business Is Yet to Catch Up With Its Share PriceWith a price-to-earnings (or "P/E") ratio of 21.5x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...分析記事 • Jan 17COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearShareholders of COSMOS Pharmaceutical Corporation ( TSE:3349 ) will be pleased this week, given that the stock price is...Reported Earnings • Jan 15Second quarter 2025 earnings: EPS exceeds analyst expectationsSecond quarter 2025 results: EPS: JP¥79.30 (up from JP¥64.09 in 2Q 2024). Revenue: JP¥244.1b (up 4.0% from 2Q 2024). Net income: JP¥6.29b (up 24% from 2Q 2024). Profit margin: 2.6% (up from 2.2% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 25%. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has remained flat.お知らせ • Jan 10Cosmos Pharmaceutical Corporation Announces Dividend for the Second Quarter-End of Fiscal Year Ending May 31, 2025, Payable on February 12, 2025COSMOS Pharmaceutical Corporation announced dividend of JPY 32.50 per share for the second quarter-end of fiscal year ending May 31, 2025 compared to JPY 60.00 per share paid a year ago. Scheduled date of commencing dividend payments: February 12, 2025.分析記事 • Dec 25Here's Why COSMOS Pharmaceutical (TSE:3349) Can Manage Its Debt ResponsiblyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Upcoming Dividend • Nov 21Upcoming dividend of JP¥32.50 per shareEligible shareholders must have bought the stock before 28 November 2024. Payment date: 13 February 2025. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Japanese dividend payers (3.8%). Lower than average of industry peers (1.6%).分析記事 • Nov 18COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The BusinessFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...お知らせ • Oct 29COSMOS Pharmaceutical Corporation to Report Q2, 2025 Results on Jan 10, 2025COSMOS Pharmaceutical Corporation announced that they will report Q2, 2025 results on Jan 10, 2025Reported Earnings • Oct 13First quarter 2025 earnings: EPS exceeds analyst expectationsFirst quarter 2025 results: EPS: JP¥103 (up from JP¥82.17 in 1Q 2024). Revenue: JP¥261.8b (up 8.4% from 1Q 2024). Net income: JP¥8.14b (up 25% from 1Q 2024). Profit margin: 3.1% (up from 2.7% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 16%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Price Target Changed • Oct 12Price target increased by 7.0% to JP¥8,198Up from JP¥7,660, the current price target is an average from 13 analysts. New target price is 12% above last closing price of JP¥7,320. Stock is up 5.9% over the past year. The company is forecast to post earnings per share of JP¥335 for next year compared to JP¥309 last year.分析記事 • Sep 26We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Declared Dividend • Sep 19Final dividend of JP¥32.50 announcedShareholders will receive a dividend of JP¥32.50. Ex-date: 28th November 2024 Payment date: 13th February 2025 Dividend yield will be 1.3%, which is lower than the industry average of 1.6%.分析記事 • Aug 17An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% UndervaluedKey Insights The projected fair value for COSMOS Pharmaceutical is JP¥23,011 based on 2 Stage Free Cash Flow to Equity...お知らせ • Aug 09COSMOS Pharmaceutical Corporation to Report Q1, 2025 Results on Oct 11, 2024COSMOS Pharmaceutical Corporation announced that they will report Q1, 2025 results on Oct 11, 2024分析記事 • Aug 01COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return TrendsIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...Reported Earnings • Jul 14Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: JP¥617 (up from JP¥601 in FY 2023). Revenue: JP¥965.0b (up 17% from FY 2023). Net income: JP¥24.5b (up 2.8% from FY 2023). Profit margin: 2.5% (down from 2.9% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.4%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 13COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 20, 2024COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 20, 2024.お知らせ • Jul 12+ 1 more updateCOSMOS Pharmaceutical Corporation Announces Year-End Dividend for the Fiscal Year Ended May 31, 2024, Payable on August 1, 2024; Provides Second Quarter End and Year End Dividend Guidance for the Fiscal Year Ending May 31, 2025COSMOS Pharmaceutical Corporation announced year-end dividend of JPY 60.00 per share for the fiscal year ended May 31, 2024 compared to JPY 57.50 per share a year ago. Scheduled date of commencing dividend payments: August 1, 2024.The company expects second quarter end dividend of JPY 32.50 per share for the fiscal year ending May 31, 2025 compared to JPY 60.00 per share a year ago.The company expects year end dividend of JPY 32.50 per share for the fiscal year ending May 31, 2025 compared to JPY 60.00 per share a year ago. Dividends per share for the fiscal year ending May 31, 2025 (forecast) take into account the effect of the said stock split.分析記事 • Jun 28Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) PriceCOSMOS Pharmaceutical Corporation's ( TSE:3349 ) price-to-earnings (or "P/E") ratio of 20.7x might make it look like a...分析記事 • Jun 10We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Upcoming Dividend • May 23Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 30 May 2024. Payment date: 05 August 2024. Payout ratio is a comfortable 9.2% but the company is paying out more than the cash it is generating. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (1.7%).分析記事 • Apr 17COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsIt's been a good week for COSMOS Pharmaceutical Corporation ( TSE:3349 ) shareholders, because the company has just...Reported Earnings • Apr 14Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: JP¥146 (up from JP¥126 in 3Q 2023). Revenue: JP¥238.9b (up 18% from 3Q 2023). Net income: JP¥5.77b (up 16% from 3Q 2023). Profit margin: 2.4% (down from 2.5% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 7.5%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year.分析記事 • Mar 16Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E RatioWith a price-to-earnings (or "P/E") ratio of 23.3x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...分析記事 • Feb 28Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning PictureIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...お知らせ • Jan 31COSMOS Pharmaceutical Corporation to Report Q3, 2024 Results on Apr 12, 2024COSMOS Pharmaceutical Corporation announced that they will report Q3, 2024 results on Apr 12, 2024Reported Earnings • Jan 14Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: EPS: JP¥128 (up from JP¥122 in 2Q 2023). Revenue: JP¥234.8b (up 19% from 2Q 2023). Net income: JP¥5.08b (up 5.4% from 2Q 2023). Profit margin: 2.2% (down from 2.4% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.9%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has remained flat.お知らせ • Jan 12+ 1 more updateCOSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024COSMOS Pharmaceutical Corporation provided consolidated earnings guidance for the fiscal year ending May 31, 2024. For the period, the company expects net sales of JPY 916,000 million, operating profit of JPY 30,200 million, profit attributable to owners of parent of JPY 23,800 million and basic earnings per share of JPY 601.03.Upcoming Dividend • Nov 22Upcoming dividend of JP¥60.00 per share at 0.8% yieldEligible shareholders must have bought the stock before 29 November 2023. Payment date: 13 February 2024. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (1.7%).お知らせ • Nov 01COSMOS Pharmaceutical Corporation to Report Q2, 2024 Results on Jan 12, 2024COSMOS Pharmaceutical Corporation announced that they will report Q2, 2024 results on Jan 12, 2024Reported Earnings • Oct 12First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2024 results: EPS: JP¥164 (up from JP¥164 in 1Q 2023). Revenue: JP¥241.7b (up 17% from 1Q 2023). Net income: JP¥6.51b (flat on 1Q 2023). Profit margin: 2.7% (down from 3.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 1.4%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 6% per year.お知らせ • Oct 11COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024COSMOS Pharmaceutical Corporation provided consolidated earnings guidance for the first half and full year of fiscal year ending May 31, 2024. For the first half, the company expects net sales of JPY 450,400 million, operating profit of JPY 14,100 million, profit attributable to owners of parent of JPY 10,577 million and basic earnings per share of JPY 267.10.For the full year, the company expects net sales of JPY 916,000 million, operating profit of JPY 30,200 million, profit attributable to owners of parent of JPY 23,800 million and basic earnings per share of JPY 601.03.Reported Earnings • Sep 05Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: JP¥601 (up from JP¥585 in FY 2022). Revenue: JP¥827.7b (up 9.6% from FY 2022). Net income: JP¥23.8b (up 2.8% from FY 2022). Profit margin: 2.9% (down from 3.1% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.4%. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.お知らせ • Aug 03COSMOS Pharmaceutical Corporation to Report Q1, 2024 Results on Oct 11, 2023COSMOS Pharmaceutical Corporation announced that they will report Q1, 2024 results on Oct 11, 2023Reported Earnings • Jul 16Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: JP¥601 (up from JP¥585 in FY 2022). Revenue: JP¥827.7b (up 9.6% from FY 2022). Net income: JP¥23.8b (up 2.8% from FY 2022). Profit margin: 2.9% (down from 3.1% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.4%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year.お知らせ • Jul 12+ 2 more updatesCOSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 22, 2023COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 22, 2023.Upcoming Dividend • May 23Upcoming dividend of JP¥42.50 per share at 0.6% yieldEligible shareholders must have bought the stock before 30 May 2023. Payment date: 24 August 2023. Payout ratio is a comfortable 14% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Japanese dividend payers (3.5%). Lower than average of industry peers (1.6%).Reported Earnings • Apr 11Third quarter 2023 earnings: EPS misses analyst expectationsThird quarter 2023 results: EPS: JP¥126 (down from JP¥132 in 3Q 2022). Revenue: JP¥202.3b (up 7.7% from 3Q 2022). Net income: JP¥4.98b (down 4.3% from 3Q 2022). Profit margin: 2.5% (down from 2.8% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.9%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 4% per year.お知らせ • Feb 09COSMOS Pharmaceutical Corporation to Report Q3, 2023 Results on Apr 10, 2023COSMOS Pharmaceutical Corporation announced that they will report Q3, 2023 results on Apr 10, 2023Reported Earnings • Jan 14Second quarter 2023 earnings: EPS misses analyst expectationsSecond quarter 2023 results: EPS: JP¥122 (down from JP¥126 in 2Q 2022). Revenue: JP¥197.9b (up 8.9% from 2Q 2022). Net income: JP¥4.82b (down 3.7% from 2Q 2022). Profit margin: 2.4% (down from 2.8% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.9%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 3% per year.お知らせ • Jan 14Cosmos Pharmaceutical Corporation Provides Earnings Forecast for the Fiscal Year Ending May 31, 2023COSMOS Pharmaceutical Corporation provided earnings Forecast for the Fiscal Year Ending May 31, 2023. For the period, The company expects Net sales of JPY 813,500 million. Operating profit of JPY 30,000 million. Profit attributable to owners of parent of JPY 23,200 million. Basic earnings per share of JPY 585.87.Upcoming Dividend • Nov 22Upcoming dividend of JP¥42.50 per shareEligible shareholders must have bought the stock before 29 November 2022. Payment date: 14 February 2023. Payout ratio is a comfortable 14% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.6%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. No independent directors (10 non-independent directors). External Director Masao Ueda was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Oct 30COSMOS Pharmaceutical Corporation to Report Q2, 2023 Results on Jan 12, 2023COSMOS Pharmaceutical Corporation announced that they will report Q2, 2023 results on Jan 12, 2023Reported Earnings • Oct 13First quarter 2023 earnings: EPS exceeds analyst expectationsFirst quarter 2023 results: EPS: JP¥164 (up from JP¥158 in 1Q 2022). Revenue: JP¥206.1b (up 8.8% from 1Q 2022). Net income: JP¥6.48b (up 3.8% from 1Q 2022). Profit margin: 3.1% (down from 3.3% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.0%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 11% per year.お知らせ • Oct 11COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Second Quarter-End and Full Year of Fiscal Year Ending May 31, 2023COSMOS Pharmaceutical Corporation provided dividend guidance for the second quarter-end and full year of fiscal year ending May 31, 2023. For the second quarter-end, the company expects to pay dividend of JPY 42.50 per share against JPY 40.00 per share paid for the same period a year ago.For the full year, the company expects to pay year-end dividend of JPY 42.50 per share against JPY 40.00 per share paid for the same period a year ago.Reported Earnings • Sep 04Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: JP¥585 (down from JP¥686 in FY 2021). Revenue: JP¥755.4b (up 4.0% from FY 2021). Net income: JP¥23.2b (down 15% from FY 2021). Profit margin: 3.1% (down from 3.7% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 8.6%, compared to a 11% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 12% per year.お知らせ • Aug 18COSMOS Pharmaceutical Corporation to Report Q1, 2023 Results on Oct 11, 2022COSMOS Pharmaceutical Corporation announced that they will report Q1, 2023 results on Oct 11, 2022お知らせ • Jul 13COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 23, 2022COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 23, 2022.Reported Earnings • Jul 13Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: JP¥585 (down from JP¥686 in FY 2021). Revenue: JP¥755.4b (up 4.0% from FY 2021). Net income: JP¥23.2b (down 15% from FY 2021). Profit margin: 3.1% (down from 3.7% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 8.9%, compared to a 18% growth forecast for the retail industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 10% per year.お知らせ • Jul 12COSMOS Pharmaceutical Corporation Announces Dividend Guidance for the Second Quarter and Year End of Fiscal Year Ending May 31, 2023COSMOS Pharmaceutical Corporation announced dividend guidance for the second quarter and year end of fiscal year ending May 31, 2023. FOr the quarter, the company expected dividend of JPY 42.50 per share.FOr the year, the company expected dividend of JPY 42.50 per share.Price Target Changed • Jun 15Price target decreased to JP¥14,800Down from JP¥16,100, the current price target is an average from 11 analysts. New target price is 28% above last closing price of JP¥11,580. Stock is down 30% over the past year. The company is forecast to post earnings per share of JP¥581 for next year compared to JP¥686 last year.Upcoming Dividend • May 23Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 30 May 2022. Payment date: 25 August 2022. Payout ratio is a comfortable 15% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.8%).お知らせ • May 12COSMOS Pharmaceutical Corporation to Report Fiscal Year 2022 Results on Jul 11, 2022COSMOS Pharmaceutical Corporation announced that they will report fiscal year 2022 results on Jul 11, 2022Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. No independent directors (10 non-independent directors). External Director Masao Ueda was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.業績と収益の成長予測TSE:3349 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数5/31/20291,375,02240,7009,500N/A15/31/20281,255,88134,9737,975N/A95/31/20271,176,94233,0826,633N/A105/31/20261,094,27031,8584,350N/A102/28/20261,069,50231,383N/AN/AN/A11/30/20251,042,62931,198-46259,529N/A8/31/20251,021,94331,006N/AN/AN/A5/31/20251,011,39030,978-85952,467N/A2/28/20251,001,94629,440N/AN/AN/A11/30/2024994,49527,2953,53553,314N/A8/31/2024985,17726,089N/AN/AN/A5/31/2024964,98924,454-63555,175N/A2/29/2024936,70624,871N/AN/AN/A11/30/2023900,11124,08568154,534N/A8/31/2023863,22823,824N/AN/AN/A5/31/2023827,69723,7977,79854,434N/A2/28/2023802,83122,983N/AN/AN/A11/30/2022788,29223,209-3,65541,973N/A8/31/2022772,12723,393N/AN/AN/A5/31/2022755,41423,155-11,30332,194N/A2/28/2022743,61222,030N/AN/AN/A11/30/2021733,38725,329-535,596N/A8/31/2021726,67225,909N/AN/AN/A5/31/2021726,42427,1561,81127,875N/A2/28/2021733,22328,777N/AN/AN/A11/30/2020723,30925,73628,88250,935N/A8/31/2020709,06423,876N/AN/AN/A5/31/2020684,40321,43539,51365,461N/A2/29/2020653,52720,217N/AN/AN/A11/30/2019638,03418,951N/A38,209N/A8/31/2019622,10319,349N/AN/AN/A5/31/2019611,13719,185N/A34,379N/A2/28/2019597,71518,966N/AN/AN/A11/30/2018585,53618,857N/A30,947N/A8/31/2018572,80717,880N/AN/AN/A5/31/2018557,99917,633N/A32,586N/A2/28/2018542,93617,510N/AN/AN/A11/30/2017526,52317,313N/A35,488N/A8/31/2017514,88018,239N/AN/AN/A5/31/2017502,73218,215N/A36,938N/A2/28/2017490,03715,812N/AN/AN/A11/30/2016477,73914,981N/A34,300N/A8/31/2016463,51713,679N/AN/AN/A5/31/2016447,27312,435N/A30,986N/A2/29/2016433,32812,738N/AN/AN/A11/30/2015423,81712,474N/A22,426N/A8/31/2015414,04612,350N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 3349の予測収益成長率 (年間5.9% ) は 貯蓄率 ( 0.8% ) を上回っています。収益対市場: 3349の収益 ( 5.9% ) JP市場 ( 9.4% ) よりも低い成長が予測されています。高成長収益: 3349の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 3349の収益 ( 7% ) JP市場 ( 6.3% ) よりも速いペースで成長すると予測されています。高い収益成長: 3349の収益 ( 7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 3349の 自己資本利益率 は、3年後には低くなると予測されています ( 11.2 %)。成長企業の発掘7D1Y7D1Y7D1YConsumer-retailing 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 19:38終値2026/06/17 00:00収益2026/02/28年間収益2025/05/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋COSMOS Pharmaceutical Corporation 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Arashi NishizawaBofA Global ResearchMitsuru TakayanagiCitigroup IncCiti ResearchCitigroup Inc15 その他のアナリストを表示
分析記事 • Apr 15COSMOS Pharmaceutical Corporation (TSE:3349) Just Released Its Third-Quarter Earnings: Here's What Analysts ThinkLast week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its quarterly result to the...
分析記事 • Jan 15COSMOS Pharmaceutical Corporation (TSE:3349) Half-Year Results Just Came Out: Here's What Analysts Are Forecasting For This YearThere's been a notable change in appetite for COSMOS Pharmaceutical Corporation ( TSE:3349 ) shares in the week since...
分析記事 • Oct 16COSMOS Pharmaceutical Corporation Just Missed EPS By 8.0%: Here's What Analysts Think Will Happen NextCOSMOS Pharmaceutical Corporation ( TSE:3349 ) shareholders are probably feeling a little disappointed, since its...
分析記事 • Jul 16Here's What Analysts Are Forecasting For COSMOS Pharmaceutical Corporation (TSE:3349) After Its Annual ResultsLast week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its annual result to the...
分析記事 • Apr 16COSMOS Pharmaceutical Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextInvestors in COSMOS Pharmaceutical Corporation ( TSE:3349 ) had a good week, as its shares rose 8.8% to close at...
分析記事 • Jan 17COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearShareholders of COSMOS Pharmaceutical Corporation ( TSE:3349 ) will be pleased this week, given that the stock price is...
Upcoming Dividend • May 21Upcoming dividend of JP¥37.50 per shareEligible shareholders must have bought the stock before 28 May 2026. Payment date: 04 August 2026. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.8%). Lower than average of industry peers (2.0%).
お知らせ • May 09COSMOS Pharmaceutical Corporation to Report Fiscal Year 2026 Results on Jul 13, 2026COSMOS Pharmaceutical Corporation announced that they will report fiscal year 2026 results on Jul 13, 2026
分析記事 • Apr 15COSMOS Pharmaceutical Corporation (TSE:3349) Just Released Its Third-Quarter Earnings: Here's What Analysts ThinkLast week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its quarterly result to the...
Reported Earnings • Apr 14Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: JP¥102 (up from JP¥99.87 in 3Q 2025). Revenue: JP¥273.2b (up 11% from 3Q 2025). Net income: JP¥8.10b (up 2.3% from 3Q 2025). Profit margin: 3.0% (down from 3.2% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 1.5%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Apr 03COSMOS Pharmaceutical Corporation to Report Q3, 2026 Results on Apr 13, 2026COSMOS Pharmaceutical Corporation announced that they will report Q3, 2026 results on Apr 13, 2026
分析記事 • Feb 16COSMOS Pharmaceutical (TSE:3349) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Declared Dividend • Feb 13First half dividend of JP¥37.50 announcedShareholders will receive a dividend of JP¥37.50. Ex-date: 28th May 2026 Payment date: 4th August 2026 Dividend yield will be 1.0%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (19% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 17% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 19% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
分析記事 • Jan 15COSMOS Pharmaceutical Corporation (TSE:3349) Half-Year Results Just Came Out: Here's What Analysts Are Forecasting For This YearThere's been a notable change in appetite for COSMOS Pharmaceutical Corporation ( TSE:3349 ) shares in the week since...
Reported Earnings • Jan 14Second quarter 2026 earnings: EPS misses analyst expectationsSecond quarter 2026 results: EPS: JP¥81.72 (up from JP¥79.30 in 2Q 2025). Revenue: JP¥264.8b (up 8.5% from 2Q 2025). Net income: JP¥6.48b (up 3.1% from 2Q 2025). Profit margin: 2.4% (down from 2.6% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.7%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 14Cosmos Pharmaceutical Corporation Announces Dividend for the Second Quarter-End of the Fiscal Year Ending May 31, 2026, Payable on February 12, 2026COSMOS Pharmaceutical Corporation announced dividend of JPY 37.50 per share for the second quarter-end of the fiscal year ending May 31, 2026 against JPY 32.50 per share paid a year ago. Scheduled date of commencing dividend payments is February 12, 2026.
分析記事 • Nov 28Returns On Capital Signal Tricky Times Ahead For COSMOS Pharmaceutical (TSE:3349)There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Upcoming Dividend • Nov 20Upcoming dividend of JP¥37.50 per shareEligible shareholders must have bought the stock before 27 November 2025. Payment date: 12 February 2026. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.5%).
分析記事 • Nov 13COSMOS Pharmaceutical (TSE:3349) Will Pay A Dividend Of ¥37.50COSMOS Pharmaceutical Corporation's ( TSE:3349 ) investors are due to receive a payment of ¥37.50 per share on 12th of...
分析記事 • Nov 12Does COSMOS Pharmaceutical (TSE:3349) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Nov 05COSMOS Pharmaceutical Corporation to Report Q2, 2026 Results on Jan 13, 2026COSMOS Pharmaceutical Corporation announced that they will report Q2, 2026 results on Jan 13, 2026
分析記事 • Oct 27COSMOS Pharmaceutical's (TSE:3349) Dividend Will Be ¥37.50The board of COSMOS Pharmaceutical Corporation ( TSE:3349 ) has announced that it will pay a dividend on the 12th of...
分析記事 • Oct 16COSMOS Pharmaceutical Corporation Just Missed EPS By 8.0%: Here's What Analysts Think Will Happen NextCOSMOS Pharmaceutical Corporation ( TSE:3349 ) shareholders are probably feeling a little disappointed, since its...
Reported Earnings • Oct 15First quarter 2026 earnings: EPS misses analyst expectationsFirst quarter 2026 results: EPS: JP¥103 (up from JP¥103 in 1Q 2025). Revenue: JP¥272.4b (up 4.0% from 1Q 2025). Net income: JP¥8.17b (flat on 1Q 2025). Profit margin: 3.0% (down from 3.1% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.0%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
分析記事 • Sep 17Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E RatioWith a price-to-earnings (or "P/E") ratio of 22.8x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...
Declared Dividend • Sep 08Final dividend of JP¥37.50 announcedShareholders will receive a dividend of JP¥37.50. Ex-date: 27th November 2025 Payment date: 12th February 2026 Dividend yield will be 0.8%, which is lower than the industry average of 1.6%.
Reported Earnings • Sep 02Full year 2025 earnings: Revenues and EPS in line with analyst expectationsFull year 2025 results: EPS: JP¥391 (up from JP¥309 in FY 2024). Revenue: JP¥1.01t (up 4.8% from FY 2024). Net income: JP¥31.0b (up 27% from FY 2024). Profit margin: 3.1% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 7% per year.
分析記事 • Aug 15Here's Why We Think COSMOS Pharmaceutical (TSE:3349) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
お知らせ • Jul 30COSMOS Pharmaceutical Corporation to Report Q1, 2026 Results on Oct 14, 2025COSMOS Pharmaceutical Corporation announced that they will report Q1, 2026 results on Oct 14, 2025
分析記事 • Jul 16Here's What Analysts Are Forecasting For COSMOS Pharmaceutical Corporation (TSE:3349) After Its Annual ResultsLast week, you might have seen that COSMOS Pharmaceutical Corporation ( TSE:3349 ) released its annual result to the...
Reported Earnings • Jul 14Full year 2025 earnings: Revenues and EPS in line with analyst expectationsFull year 2025 results: EPS: JP¥391 (up from JP¥309 in FY 2024). Revenue: JP¥1.01t (up 4.8% from FY 2024). Net income: JP¥31.0b (up 27% from FY 2024). Profit margin: 3.1% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 8% per year.
お知らせ • Jul 13+ 3 more updatesCOSMOS Pharmaceutical Corporation Announces Year-End Dividend for the Fiscal Year Ended May 31, 2025, Payable on August 4, 2025COSMOS Pharmaceutical Corporation resolved to distribute dividends of surplus with a record date of May 31, 2025. The details of which are as below. Record date: May 31, 2025,Dividend per share JPY 37.50. Total amount of dividends: JPY 2,972 million . Effective date: August 4, 2025 Source of dividends Retained earnings as compared to the dividend of JPY 60.00 (JPY 30.00) per share paid an year ago. The Company conducted a 2-for-1 stock split effective September 1, 2024. Dividends per share for the fiscal year ended May 31, 2024 are based on the number of shares before such stock split. For your reference, the figure shown in parentheses represents the amount per share reflecting the aforementioned stock split.
お知らせ • Jul 11COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 21, 2025COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 21, 2025.
分析記事 • Jul 04Return Trends At COSMOS Pharmaceutical (TSE:3349) Aren't AppealingTo find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...
分析記事 • Jun 02Is COSMOS Pharmaceutical (TSE:3349) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Upcoming Dividend • May 22Upcoming dividend of JP¥32.50 per shareEligible shareholders must have bought the stock before 29 May 2025. Payment date: 01 August 2025. Payout ratio is a comfortable 17% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Japanese dividend payers (4.0%). Lower than average of industry peers (1.7%).
分析記事 • May 17Investor Optimism Abounds COSMOS Pharmaceutical Corporation (TSE:3349) But Growth Is LackingWith a price-to-earnings (or "P/E") ratio of 24.7x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...
お知らせ • May 01COSMOS Pharmaceutical Corporation to Report Fiscal Year 2025 Results on Jul 11, 2025COSMOS Pharmaceutical Corporation announced that they will report fiscal year 2025 results on Jul 11, 2025
分析記事 • Apr 16COSMOS Pharmaceutical Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextInvestors in COSMOS Pharmaceutical Corporation ( TSE:3349 ) had a good week, as its shares rose 8.8% to close at...
Reported Earnings • Apr 15Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: EPS: JP¥99.87 (up from JP¥72.80 in 3Q 2024). Revenue: JP¥246.3b (up 3.1% from 3Q 2024). Net income: JP¥7.92b (up 37% from 3Q 2024). Profit margin: 3.2% (up from 2.4% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 31%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 12% per year.
分析記事 • Mar 27Should You Be Adding COSMOS Pharmaceutical (TSE:3349) To Your Watchlist Today?It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
分析記事 • Mar 11COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The BusinessFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Declared Dividend • Feb 13First half dividend of JP¥32.50 announcedShareholders will receive a dividend of JP¥32.50. Ex-date: 29th May 2025 Payment date: 1st August 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.6%. Payout Ratios Payout ratio: 18%. Cash payout ratio: 146%.
お知らせ • Feb 03COSMOS Pharmaceutical Corporation to Report Q3, 2025 Results on Apr 11, 2025COSMOS Pharmaceutical Corporation announced that they will report Q3, 2025 results on Apr 11, 2025
分析記事 • Jan 31COSMOS Pharmaceutical Corporation's (TSE:3349) Business Is Yet to Catch Up With Its Share PriceWith a price-to-earnings (or "P/E") ratio of 21.5x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...
分析記事 • Jan 17COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearShareholders of COSMOS Pharmaceutical Corporation ( TSE:3349 ) will be pleased this week, given that the stock price is...
Reported Earnings • Jan 15Second quarter 2025 earnings: EPS exceeds analyst expectationsSecond quarter 2025 results: EPS: JP¥79.30 (up from JP¥64.09 in 2Q 2024). Revenue: JP¥244.1b (up 4.0% from 2Q 2024). Net income: JP¥6.29b (up 24% from 2Q 2024). Profit margin: 2.6% (up from 2.2% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 25%. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has remained flat.
お知らせ • Jan 10Cosmos Pharmaceutical Corporation Announces Dividend for the Second Quarter-End of Fiscal Year Ending May 31, 2025, Payable on February 12, 2025COSMOS Pharmaceutical Corporation announced dividend of JPY 32.50 per share for the second quarter-end of fiscal year ending May 31, 2025 compared to JPY 60.00 per share paid a year ago. Scheduled date of commencing dividend payments: February 12, 2025.
分析記事 • Dec 25Here's Why COSMOS Pharmaceutical (TSE:3349) Can Manage Its Debt ResponsiblyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Upcoming Dividend • Nov 21Upcoming dividend of JP¥32.50 per shareEligible shareholders must have bought the stock before 28 November 2024. Payment date: 13 February 2025. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Japanese dividend payers (3.8%). Lower than average of industry peers (1.6%).
分析記事 • Nov 18COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The BusinessFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
お知らせ • Oct 29COSMOS Pharmaceutical Corporation to Report Q2, 2025 Results on Jan 10, 2025COSMOS Pharmaceutical Corporation announced that they will report Q2, 2025 results on Jan 10, 2025
Reported Earnings • Oct 13First quarter 2025 earnings: EPS exceeds analyst expectationsFirst quarter 2025 results: EPS: JP¥103 (up from JP¥82.17 in 1Q 2024). Revenue: JP¥261.8b (up 8.4% from 1Q 2024). Net income: JP¥8.14b (up 25% from 1Q 2024). Profit margin: 3.1% (up from 2.7% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 16%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Price Target Changed • Oct 12Price target increased by 7.0% to JP¥8,198Up from JP¥7,660, the current price target is an average from 13 analysts. New target price is 12% above last closing price of JP¥7,320. Stock is up 5.9% over the past year. The company is forecast to post earnings per share of JP¥335 for next year compared to JP¥309 last year.
分析記事 • Sep 26We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Declared Dividend • Sep 19Final dividend of JP¥32.50 announcedShareholders will receive a dividend of JP¥32.50. Ex-date: 28th November 2024 Payment date: 13th February 2025 Dividend yield will be 1.3%, which is lower than the industry average of 1.6%.
分析記事 • Aug 17An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% UndervaluedKey Insights The projected fair value for COSMOS Pharmaceutical is JP¥23,011 based on 2 Stage Free Cash Flow to Equity...
お知らせ • Aug 09COSMOS Pharmaceutical Corporation to Report Q1, 2025 Results on Oct 11, 2024COSMOS Pharmaceutical Corporation announced that they will report Q1, 2025 results on Oct 11, 2024
分析記事 • Aug 01COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return TrendsIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...
Reported Earnings • Jul 14Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: JP¥617 (up from JP¥601 in FY 2023). Revenue: JP¥965.0b (up 17% from FY 2023). Net income: JP¥24.5b (up 2.8% from FY 2023). Profit margin: 2.5% (down from 2.9% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.4%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 13COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 20, 2024COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 20, 2024.
お知らせ • Jul 12+ 1 more updateCOSMOS Pharmaceutical Corporation Announces Year-End Dividend for the Fiscal Year Ended May 31, 2024, Payable on August 1, 2024; Provides Second Quarter End and Year End Dividend Guidance for the Fiscal Year Ending May 31, 2025COSMOS Pharmaceutical Corporation announced year-end dividend of JPY 60.00 per share for the fiscal year ended May 31, 2024 compared to JPY 57.50 per share a year ago. Scheduled date of commencing dividend payments: August 1, 2024.The company expects second quarter end dividend of JPY 32.50 per share for the fiscal year ending May 31, 2025 compared to JPY 60.00 per share a year ago.The company expects year end dividend of JPY 32.50 per share for the fiscal year ending May 31, 2025 compared to JPY 60.00 per share a year ago. Dividends per share for the fiscal year ending May 31, 2025 (forecast) take into account the effect of the said stock split.
分析記事 • Jun 28Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) PriceCOSMOS Pharmaceutical Corporation's ( TSE:3349 ) price-to-earnings (or "P/E") ratio of 20.7x might make it look like a...
分析記事 • Jun 10We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Upcoming Dividend • May 23Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 30 May 2024. Payment date: 05 August 2024. Payout ratio is a comfortable 9.2% but the company is paying out more than the cash it is generating. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (1.7%).
分析記事 • Apr 17COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsIt's been a good week for COSMOS Pharmaceutical Corporation ( TSE:3349 ) shareholders, because the company has just...
Reported Earnings • Apr 14Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: JP¥146 (up from JP¥126 in 3Q 2023). Revenue: JP¥238.9b (up 18% from 3Q 2023). Net income: JP¥5.77b (up 16% from 3Q 2023). Profit margin: 2.4% (down from 2.5% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 7.5%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year.
分析記事 • Mar 16Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E RatioWith a price-to-earnings (or "P/E") ratio of 23.3x COSMOS Pharmaceutical Corporation ( TSE:3349 ) may be sending very...
分析記事 • Feb 28Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning PictureIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
お知らせ • Jan 31COSMOS Pharmaceutical Corporation to Report Q3, 2024 Results on Apr 12, 2024COSMOS Pharmaceutical Corporation announced that they will report Q3, 2024 results on Apr 12, 2024
Reported Earnings • Jan 14Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: EPS: JP¥128 (up from JP¥122 in 2Q 2023). Revenue: JP¥234.8b (up 19% from 2Q 2023). Net income: JP¥5.08b (up 5.4% from 2Q 2023). Profit margin: 2.2% (down from 2.4% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.9%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has remained flat.
お知らせ • Jan 12+ 1 more updateCOSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024COSMOS Pharmaceutical Corporation provided consolidated earnings guidance for the fiscal year ending May 31, 2024. For the period, the company expects net sales of JPY 916,000 million, operating profit of JPY 30,200 million, profit attributable to owners of parent of JPY 23,800 million and basic earnings per share of JPY 601.03.
Upcoming Dividend • Nov 22Upcoming dividend of JP¥60.00 per share at 0.8% yieldEligible shareholders must have bought the stock before 29 November 2023. Payment date: 13 February 2024. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (1.7%).
お知らせ • Nov 01COSMOS Pharmaceutical Corporation to Report Q2, 2024 Results on Jan 12, 2024COSMOS Pharmaceutical Corporation announced that they will report Q2, 2024 results on Jan 12, 2024
Reported Earnings • Oct 12First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2024 results: EPS: JP¥164 (up from JP¥164 in 1Q 2023). Revenue: JP¥241.7b (up 17% from 1Q 2023). Net income: JP¥6.51b (flat on 1Q 2023). Profit margin: 2.7% (down from 3.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 1.4%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 6% per year.
お知らせ • Oct 11COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024COSMOS Pharmaceutical Corporation provided consolidated earnings guidance for the first half and full year of fiscal year ending May 31, 2024. For the first half, the company expects net sales of JPY 450,400 million, operating profit of JPY 14,100 million, profit attributable to owners of parent of JPY 10,577 million and basic earnings per share of JPY 267.10.For the full year, the company expects net sales of JPY 916,000 million, operating profit of JPY 30,200 million, profit attributable to owners of parent of JPY 23,800 million and basic earnings per share of JPY 601.03.
Reported Earnings • Sep 05Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: JP¥601 (up from JP¥585 in FY 2022). Revenue: JP¥827.7b (up 9.6% from FY 2022). Net income: JP¥23.8b (up 2.8% from FY 2022). Profit margin: 2.9% (down from 3.1% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.4%. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.
お知らせ • Aug 03COSMOS Pharmaceutical Corporation to Report Q1, 2024 Results on Oct 11, 2023COSMOS Pharmaceutical Corporation announced that they will report Q1, 2024 results on Oct 11, 2023
Reported Earnings • Jul 16Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: JP¥601 (up from JP¥585 in FY 2022). Revenue: JP¥827.7b (up 9.6% from FY 2022). Net income: JP¥23.8b (up 2.8% from FY 2022). Profit margin: 2.9% (down from 3.1% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.4%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year.
お知らせ • Jul 12+ 2 more updatesCOSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 22, 2023COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 22, 2023.
Upcoming Dividend • May 23Upcoming dividend of JP¥42.50 per share at 0.6% yieldEligible shareholders must have bought the stock before 30 May 2023. Payment date: 24 August 2023. Payout ratio is a comfortable 14% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Japanese dividend payers (3.5%). Lower than average of industry peers (1.6%).
Reported Earnings • Apr 11Third quarter 2023 earnings: EPS misses analyst expectationsThird quarter 2023 results: EPS: JP¥126 (down from JP¥132 in 3Q 2022). Revenue: JP¥202.3b (up 7.7% from 3Q 2022). Net income: JP¥4.98b (down 4.3% from 3Q 2022). Profit margin: 2.5% (down from 2.8% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.9%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 4% per year.
お知らせ • Feb 09COSMOS Pharmaceutical Corporation to Report Q3, 2023 Results on Apr 10, 2023COSMOS Pharmaceutical Corporation announced that they will report Q3, 2023 results on Apr 10, 2023
Reported Earnings • Jan 14Second quarter 2023 earnings: EPS misses analyst expectationsSecond quarter 2023 results: EPS: JP¥122 (down from JP¥126 in 2Q 2022). Revenue: JP¥197.9b (up 8.9% from 2Q 2022). Net income: JP¥4.82b (down 3.7% from 2Q 2022). Profit margin: 2.4% (down from 2.8% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.9%. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 3% per year.
お知らせ • Jan 14Cosmos Pharmaceutical Corporation Provides Earnings Forecast for the Fiscal Year Ending May 31, 2023COSMOS Pharmaceutical Corporation provided earnings Forecast for the Fiscal Year Ending May 31, 2023. For the period, The company expects Net sales of JPY 813,500 million. Operating profit of JPY 30,000 million. Profit attributable to owners of parent of JPY 23,200 million. Basic earnings per share of JPY 585.87.
Upcoming Dividend • Nov 22Upcoming dividend of JP¥42.50 per shareEligible shareholders must have bought the stock before 29 November 2022. Payment date: 14 February 2023. Payout ratio is a comfortable 14% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.6%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. No independent directors (10 non-independent directors). External Director Masao Ueda was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Oct 30COSMOS Pharmaceutical Corporation to Report Q2, 2023 Results on Jan 12, 2023COSMOS Pharmaceutical Corporation announced that they will report Q2, 2023 results on Jan 12, 2023
Reported Earnings • Oct 13First quarter 2023 earnings: EPS exceeds analyst expectationsFirst quarter 2023 results: EPS: JP¥164 (up from JP¥158 in 1Q 2022). Revenue: JP¥206.1b (up 8.8% from 1Q 2022). Net income: JP¥6.48b (up 3.8% from 1Q 2022). Profit margin: 3.1% (down from 3.3% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.0%. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 11% per year.
お知らせ • Oct 11COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Second Quarter-End and Full Year of Fiscal Year Ending May 31, 2023COSMOS Pharmaceutical Corporation provided dividend guidance for the second quarter-end and full year of fiscal year ending May 31, 2023. For the second quarter-end, the company expects to pay dividend of JPY 42.50 per share against JPY 40.00 per share paid for the same period a year ago.For the full year, the company expects to pay year-end dividend of JPY 42.50 per share against JPY 40.00 per share paid for the same period a year ago.
Reported Earnings • Sep 04Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: JP¥585 (down from JP¥686 in FY 2021). Revenue: JP¥755.4b (up 4.0% from FY 2021). Net income: JP¥23.2b (down 15% from FY 2021). Profit margin: 3.1% (down from 3.7% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 8.6%, compared to a 11% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 12% per year.
お知らせ • Aug 18COSMOS Pharmaceutical Corporation to Report Q1, 2023 Results on Oct 11, 2022COSMOS Pharmaceutical Corporation announced that they will report Q1, 2023 results on Oct 11, 2022
お知らせ • Jul 13COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 23, 2022COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 23, 2022.
Reported Earnings • Jul 13Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: JP¥585 (down from JP¥686 in FY 2021). Revenue: JP¥755.4b (up 4.0% from FY 2021). Net income: JP¥23.2b (down 15% from FY 2021). Profit margin: 3.1% (down from 3.7% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 8.9%, compared to a 18% growth forecast for the retail industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 10% per year.
お知らせ • Jul 12COSMOS Pharmaceutical Corporation Announces Dividend Guidance for the Second Quarter and Year End of Fiscal Year Ending May 31, 2023COSMOS Pharmaceutical Corporation announced dividend guidance for the second quarter and year end of fiscal year ending May 31, 2023. FOr the quarter, the company expected dividend of JPY 42.50 per share.FOr the year, the company expected dividend of JPY 42.50 per share.
Price Target Changed • Jun 15Price target decreased to JP¥14,800Down from JP¥16,100, the current price target is an average from 11 analysts. New target price is 28% above last closing price of JP¥11,580. Stock is down 30% over the past year. The company is forecast to post earnings per share of JP¥581 for next year compared to JP¥686 last year.
Upcoming Dividend • May 23Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 30 May 2022. Payment date: 25 August 2022. Payout ratio is a comfortable 15% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (1.8%).
お知らせ • May 12COSMOS Pharmaceutical Corporation to Report Fiscal Year 2022 Results on Jul 11, 2022COSMOS Pharmaceutical Corporation announced that they will report fiscal year 2022 results on Jul 11, 2022
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. No independent directors (10 non-independent directors). External Director Masao Ueda was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.